Artículos

Psychedelics for the treatment of psychiatric disorders: interpreting and translating available evidence and guidance for future research / McIntyre, Roger S. en The American Journal of Psychiatry, Año 2025 - Vol. 182 - No.1 (Enero)

Público ISBD [artículo]  inThe American Journal of Psychiatry > Año 2025 - Vol. 182 - No.1 (Enero) . - pp. 21–32 Título : Psychedelics for the treatment of psychiatric disorders: interpreting and translating available evidence and guidance for future research Tipo de documento: texto impreso Autores: McIntyre, Roger S., Autor Fecha de publicación: 2025 Artículo en la página: pp. 21–32 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Trastorno por consumo de alcohol, Trastornos depresivos, Metodología, Trastorno de estrés postraumático (TEPT), Psicodélicos, Trastornos adictivos y relacionados con sustancias. Resumen: During the past decade, there has been extraordinary public, media, and medical research interest in psychedelics as promising therapeutics for difficult-to-treat psychiatric disorders. Short-term controlled trial data suggest that certain psychedelics are effective and safe in the treatment of major depressive disorder, treatment-resistant depression, and posttraumatic stress disorder. Link: ./index.php?lvl=notice_display&id=31556 [artículo] Psychedelics for the treatment of psychiatric disorders: interpreting and translating available evidence and guidance for future research [texto impreso] / McIntyre, Roger S., Autor . - 2025 . - pp. 21–32. Idioma : Inglés (eng) Idioma original : Inglés (eng) in The American Journal of Psychiatry > Año 2025 - Vol. 182 - No.1 (Enero) . - pp. 21–32 Palabras clave: Trastorno por consumo de alcohol, Trastornos depresivos, Metodología, Trastorno de estrés postraumático (TEPT), Psicodélicos, Trastornos adictivos y relacionados con sustancias. Resumen: During the past decade, there has been extraordinary public, media, and medical research interest in psychedelics as promising therapeutics for difficult-to-treat psychiatric disorders. Short-term controlled trial data suggest that certain psychedelics are effective and safe in the treatment of major depressive disorder, treatment-resistant depression, and posttraumatic stress disorder. Link: ./index.php?lvl=notice_display&id=31556

Benefits and challenges of ultra-fast, short-acting psychedelics in the treatment of depression / Johannes G. Ramaekers en The American Journal of Psychiatry, Año 2025 - Vol. 182 - No.1 (Enero)

Público ISBD [artículo]  inThe American Journal of Psychiatry > Año 2025 - Vol. 182 - No.1 (Enero) . - pp. 33-46 Título : Benefits and challenges of ultra-fast, short-acting psychedelics in the treatment of depression Tipo de documento: texto impreso Autores: Johannes G. Ramaekers, Autor ; Johannes T. Reckweg, Autor ; Natasha L. Mason, Autor Fecha de publicación: 2025 Artículo en la página: pp. 33-46 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: 5-MeO-DMT, DMT, Depresión, Psicodélicos. Resumen: Unlike classical antidepressants, psychedelics such as psilocybin have been shown to induce a rapid antidepressant response. In the wake of this development, interest has emerged in ultra-fast, short-acting psychedelics such as 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) and N,N-dimethyltryptamine (DMT) with the expectation that these can produce rapid antidepressant effects following an intense but brief psychedelic intervention. Link: ./index.php?lvl=notice_display&id=31557 [artículo] Benefits and challenges of ultra-fast, short-acting psychedelics in the treatment of depression [texto impreso] / Johannes G. Ramaekers, Autor ; Johannes T. Reckweg, Autor ; Natasha L. Mason, Autor . - 2025 . - pp. 33-46. Idioma : Inglés (eng) Idioma original : Inglés (eng) in The American Journal of Psychiatry > Año 2025 - Vol. 182 - No.1 (Enero) . - pp. 33-46 Palabras clave: 5-MeO-DMT, DMT, Depresión, Psicodélicos. Resumen: Unlike classical antidepressants, psychedelics such as psilocybin have been shown to induce a rapid antidepressant response. In the wake of this development, interest has emerged in ultra-fast, short-acting psychedelics such as 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) and N,N-dimethyltryptamine (DMT) with the expectation that these can produce rapid antidepressant effects following an intense but brief psychedelic intervention. Link: ./index.php?lvl=notice_display&id=31557

Primum non nocere: the onus to characterize the potential harms of psychedelic treatment / Sharmin Ghaznavi en The American Journal of Psychiatry, Año 2025 - Vol. 182 - No.1 (Enero)

Público ISBD [artículo]  inThe American Journal of Psychiatry > Año 2025 - Vol. 182 - No.1 (Enero) . - pp. 47-53 Título : Primum non nocere: the onus to characterize the potential harms of psychedelic treatment Tipo de documento: texto impreso Autores: Sharmin Ghaznavi, Autor ; Jeremy N. Ruskin, Autor ; Stephen J. Haggerty, Autor Fecha de publicación: 2025 Artículo en la página: pp. 47-53 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Efectos adversos, Ética, Psicodélicos, Riesgos. Resumen: The last few years have seen exponential growth in interest, investment, advocacy, and research into psychedelics as therapeutics. This reflects an optimism about the potential promise of psychedelics as therapeutics. As with all therapeutic interventions, research is needed not only into their benefits but also potential risks. Link: ./index.php?lvl=notice_display&id=31558 [artículo] Primum non nocere: the onus to characterize the potential harms of psychedelic treatment [texto impreso] / Sharmin Ghaznavi, Autor ; Jeremy N. Ruskin, Autor ; Stephen J. Haggerty, Autor . - 2025 . - pp. 47-53. Idioma : Inglés (eng) Idioma original : Inglés (eng) in The American Journal of Psychiatry > Año 2025 - Vol. 182 - No.1 (Enero) . - pp. 47-53 Palabras clave: Efectos adversos, Ética, Psicodélicos, Riesgos. Resumen: The last few years have seen exponential growth in interest, investment, advocacy, and research into psychedelics as therapeutics. This reflects an optimism about the potential promise of psychedelics as therapeutics. As with all therapeutic interventions, research is needed not only into their benefits but also potential risks. Link: ./index.php?lvl=notice_display&id=31558

Psilocybin: from psychiatric pariah to perceived panacea / Aaron S. Wolfgang ; Bryan R. Barksdale en The American Journal of Psychiatry, Año 2025 - Vol. 182 - No.1 (Enero)

Público ISBD [artículo]  inThe American Journal of Psychiatry > Año 2025 - Vol. 182 - No.1 (Enero) . - pp. 54-78 Título : Psilocybin: from psychiatric pariah to perceived panacea Tipo de documento: texto impreso Autores: Aaron S. Wolfgang, Autor ; Bryan R. Barksdale, Autor Fecha de publicación: 2025 Artículo en la página: pp. 54-78 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Ansiedad, Depresión, Psilocibina, Trastornos psiquiátricos, Apoyo / terapia psicológica. Resumen: The authors critically examine the evidence base for psilocybin administered with psychological support/therapy (PST) in the treatment of psychiatric disorders and offer practical recommendations to guide future research endeavors. Link: ./index.php?lvl=notice_display&id=31559 [artículo] Psilocybin: from psychiatric pariah to perceived panacea [texto impreso] / Aaron S. Wolfgang, Autor ; Bryan R. Barksdale, Autor . - 2025 . - pp. 54-78. Idioma : Inglés (eng) Idioma original : Inglés (eng) in The American Journal of Psychiatry > Año 2025 - Vol. 182 - No.1 (Enero) . - pp. 54-78 Palabras clave: Ansiedad, Depresión, Psilocibina, Trastornos psiquiátricos, Apoyo / terapia psicológica. Resumen: The authors critically examine the evidence base for psilocybin administered with psychological support/therapy (PST) in the treatment of psychiatric disorders and offer practical recommendations to guide future research endeavors. Link: ./index.php?lvl=notice_display&id=31559

MDMA and MDMA- assisted therapy / Aaron S. Wolfgang en The American Journal of Psychiatry, Año 2025 - Vol. 182 - No.1 (Enero)

Público ISBD [artículo]  inThe American Journal of Psychiatry > Año 2025 - Vol. 182 - No.1 (Enero) . - pp. 79-103 Título : MDMA and MDMA- assisted therapy Tipo de documento: texto impreso Autores: Aaron S. Wolfgang, Autor ; Gregory A. Fonzo, Autor ; Joshua C. Gray, Autor Fecha de publicación: 2025 Artículo en la página: pp. 79-103 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Estudios clínicos de medicamentos, Trastornos depresivos, MDMA, Trastorno depresivo mayor, Trastorno de estrés postraumático (TEPT). Resumen: MDMA (i.e., 3,4-methylenedixoymethamphetamine), commonly known as “Ecstasy” or “Molly,” has been used since the 1970s both in recreational and therapeutic settings. The Food and Drug Administration (FDA) designated MDMA-Assisted Therapy (MDMA-AT) as a Breakthrough Therapy for posttraumatic stress disorder (PTSD) in 2017, and the FDA is requiring an additional phase 3 trial after rejecting the initial New Drug Application in 2024. Link: ./index.php?lvl=notice_display&id=31560 [artículo] MDMA and MDMA- assisted therapy [texto impreso] / Aaron S. Wolfgang, Autor ; Gregory A. Fonzo, Autor ; Joshua C. Gray, Autor . - 2025 . - pp. 79-103. Idioma : Inglés (eng) Idioma original : Inglés (eng) in The American Journal of Psychiatry > Año 2025 - Vol. 182 - No.1 (Enero) . - pp. 79-103 Palabras clave: Estudios clínicos de medicamentos, Trastornos depresivos, MDMA, Trastorno depresivo mayor, Trastorno de estrés postraumático (TEPT). Resumen: MDMA (i.e., 3,4-methylenedixoymethamphetamine), commonly known as “Ecstasy” or “Molly,” has been used since the 1970s both in recreational and therapeutic settings. The Food and Drug Administration (FDA) designated MDMA-Assisted Therapy (MDMA-AT) as a Breakthrough Therapy for posttraumatic stress disorder (PTSD) in 2017, and the FDA is requiring an additional phase 3 trial after rejecting the initial New Drug Application in 2024. Link: ./index.php?lvl=notice_display&id=31560

Single-dose psilocybin for depression with severe treatment resistance: an open-label trial / Scott T. Aaronson en The American Journal of Psychiatry, Año 2025 - Vol. 182 - No.1 (Enero)

Público ISBD [artículo]  inThe American Journal of Psychiatry > Año 2025 - Vol. 182 - No.1 (Enero) . - pp. 104-113 Título : Single-dose psilocybin for depression with severe treatment resistance: an open-label trial Tipo de documento: texto impreso Autores: Scott T. Aaronson, Autor ; Andrew Van der Vaart, Autor ; Tammy Miller, Autor Fecha de publicación: 2025 Artículo en la página: pp. 104-113 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Estudios clínicos de medicamentos, Trastornos depresivos, Combinación de fármacos y psicoterapia, Trastorno depresivo mayor, Psicodélicos, Psicofarmacología. Resumen: Depression varies along a difficulty-to-treat spectrum. Patients whose illness fails to respond to at least five treatments may be considered to have severely treatment-resistant depression (TRD). The objective of this study was to document the safety and efficacy of psilocybin in patients with severe TRD. Link: ./index.php?lvl=notice_display&id=31561 [artículo] Single-dose psilocybin for depression with severe treatment resistance: an open-label trial [texto impreso] / Scott T. Aaronson, Autor ; Andrew Van der Vaart, Autor ; Tammy Miller, Autor . - 2025 . - pp. 104-113. Idioma : Inglés (eng) Idioma original : Inglés (eng) in The American Journal of Psychiatry > Año 2025 - Vol. 182 - No.1 (Enero) . - pp. 104-113 Palabras clave: Estudios clínicos de medicamentos, Trastornos depresivos, Combinación de fármacos y psicoterapia, Trastorno depresivo mayor, Psicodélicos, Psicofarmacología. Resumen: Depression varies along a difficulty-to-treat spectrum. Patients whose illness fails to respond to at least five treatments may be considered to have severely treatment-resistant depression (TRD). The objective of this study was to document the safety and efficacy of psilocybin in patients with severe TRD. Link: ./index.php?lvl=notice_display&id=31561

Multidimensional personality changes following psilocybin-assisted therapy in patients with alcohol use disorder: results from a double-blind, placebo-controlled clinical trial / Broc A. Pagni en The American Journal of Psychiatry, Año 2025 - Vol. 182 - No.1 (Enero)

Público ISBD [artículo]  inThe American Journal of Psychiatry > Año 2025 - Vol. 182 - No.1 (Enero) . - pp. 114-125 Título : Multidimensional personality changes following psilocybin-assisted therapy in patients with alcohol use disorder: results from a double-blind, placebo-controlled clinical trial Tipo de documento: texto impreso Autores: Broc A. Pagni, Autor ; Richard J. Zeifman, Autor ; Sarah E. Mennenga, Autor Fecha de publicación: 2025 Artículo en la página: pp. 114-125 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Dependencia del alcohol, Impulsividad, Personalidad, Terapia con psilocibina, Psicodélico. Resumen: Evidence suggests that psilocybin-assisted therapy (PAT) leads to durable shifts in personality structure. However, such changes have yet to be characterized in disorders of addiction. In this secondary analysis from a randomized controlled trial, the authors examined the effect of PAT on personality dimensions in patients with alcohol use disorder (AUD), hypothesizing that PAT would attenuate personality abnormalities in AUD and that reductions in trait impulsiveness would be associated with lower drinking. Link: ./index.php?lvl=notice_display&id=31562 [artículo] Multidimensional personality changes following psilocybin-assisted therapy in patients with alcohol use disorder: results from a double-blind, placebo-controlled clinical trial [texto impreso] / Broc A. Pagni, Autor ; Richard J. Zeifman, Autor ; Sarah E. Mennenga, Autor . - 2025 . - pp. 114-125. Idioma : Inglés (eng) Idioma original : Inglés (eng) in The American Journal of Psychiatry > Año 2025 - Vol. 182 - No.1 (Enero) . - pp. 114-125 Palabras clave: Dependencia del alcohol, Impulsividad, Personalidad, Terapia con psilocibina, Psicodélico. Resumen: Evidence suggests that psilocybin-assisted therapy (PAT) leads to durable shifts in personality structure. However, such changes have yet to be characterized in disorders of addiction. In this secondary analysis from a randomized controlled trial, the authors examined the effect of PAT on personality dimensions in patients with alcohol use disorder (AUD), hypothesizing that PAT would attenuate personality abnormalities in AUD and that reductions in trait impulsiveness would be associated with lower drinking. Link: ./index.php?lvl=notice_display&id=31562

Compass psychological support model for comp360 psilocybin treatment of serious mental health conditions / Namik Kirlić en The American Journal of Psychiatry, Año 2025 - Vol. 182 - No.1 (Enero)

Público ISBD [artículo]  inThe American Journal of Psychiatry > Año 2025 - Vol. 182 - No.1 (Enero) . - pp. 126-132 Título : Compass psychological support model for comp360 psilocybin treatment of serious mental health conditions Tipo de documento: texto impreso Autores: Namik Kirlić, Autor ; Molly Lennard Jones, Autor ; Merve Atli, Autor Fecha de publicación: 2025 Artículo en la página: pp. 126-132 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Estudios clínicos de medicamentos, Trastornos depresivos, Combinación de fármacos y psicoterapia, Trastorno depresivo mayor. Resumen: The psychedelic experience can be challenging. There is a need for a structured framework for providing psychological support to individuals with mental health conditions receiving investigational psilocybin treatment. The primary benefit of such a framework is to support a safe and meaningful psilocybin experience. It also enables future research on the facets of psychological support and/or psychotherapy that most optimally complement psilocybin treatment. Link: ./index.php?lvl=notice_display&id=31563 [artículo] Compass psychological support model for comp360 psilocybin treatment of serious mental health conditions [texto impreso] / Namik Kirlić, Autor ; Molly Lennard Jones, Autor ; Merve Atli, Autor . - 2025 . - pp. 126-132. Idioma : Inglés (eng) Idioma original : Inglés (eng) in The American Journal of Psychiatry > Año 2025 - Vol. 182 - No.1 (Enero) . - pp. 126-132 Palabras clave: Estudios clínicos de medicamentos, Trastornos depresivos, Combinación de fármacos y psicoterapia, Trastorno depresivo mayor. Resumen: The psychedelic experience can be challenging. There is a need for a structured framework for providing psychological support to individuals with mental health conditions receiving investigational psilocybin treatment. The primary benefit of such a framework is to support a safe and meaningful psilocybin experience. It also enables future research on the facets of psychological support and/or psychotherapy that most optimally complement psilocybin treatment. Link: ./index.php?lvl=notice_display&id=31563